NIKKEI 225
38,460.08 0.00 (0.00%) HANG SENG
17,201.27 +372.34 (+2.21%) CRUDE OIL
82.68 -0.13 (-0.16%) GOLD FUTURES
2,328.00 -10.40 (-0.44%) DOW
38,460.92 -42.77 (-0.11%) Bitcoin GBP
51,632.72 -1,828.32 (-3.42%)
Medigene AG (MDG1.BE)
| Previous close | 1.7250 |
| Open | 1.5500 |
| Bid | 1.5750 x 0 |
| Ask | 1.6150 x 0 |
| Day's range | 1.5500 - 1.6650 |
| 52-week range | 1.3750 - 2.6500 |
| Volume | |
| Avg. volume | 84 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Medigene to Present at Upcoming Scientific Conferences
Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, has been invited to present at the CHI's 8th Annual Immuno-Oncology Summit Europe from April 23-25, 2024, in London, UK, as well as at the 7th International Neoantigen Summit to be held in Amsterdam, Netherlands from April 29 - May 1, 2024. The presentations will be available on Medigene´s website after the c
- Globe Newswire
Medigene Presents Favorable Safety Profile of TCR-T Cells with Costimulatory Switch Protein at AACR Annual Meeting 2024
Planegg/Martinsried, April 8, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today presents superior recombinant T cell receptor (rTCR) engineered T cell functionality as well as a favorable safety profile when rTCR-T cells are armored and enhanced with the PD1-41BB costimulatory switch protein (CSP) at the American Association for Cancer Research (
- Globe Newswire
Medigene AG Secures European Patent for its iM-TCR Technology
Planegg/Martinsried, April 4, 2024. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today announced that the Company has been issued a patent by the European Patent Office protecting its inducible Medigene T cell receptor (iM-TCR) technology, which contains a control mechanism to regulate efficacy and improve safety of its T cell receptor engineered T cell (TCR-T) therapie
